Topics:

Trial of Tykerb for HER2-Positive Breast Cancer Brain Mets Begins

Trial of Tykerb for HER2-Positive Breast Cancer Brain Mets Begins

SAN ANTONIO—GlaxoSmithKline has announced the initiation of a global multicenter phase II trial (known as EGF 105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2 (HER2)-overexpressing breast cancer that has metastasized to the brain. Tykerb is an orally bioavailable small molecule that potently inhibits two receptors, ErbB2 and ErbB1. It is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.

 
Loading comments...
Please Wait 20 seconds or click here to close